---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-083431"
form_type: "8-K"
ticker: "VYGR"
cik: "0001640266"
company_name: "Voyager Therapeutics, Inc."
filed_at: "2022-07-28T23:59:59+00:00"
generated_at: "2026-06-24T07:33:51.283157+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Voyager Therapeutics appoints Catherine J. Mackey, Ph.D. to Board of Directors

## Summary
- Dr. Mackey appointed as Class I director effective August 15, 2022, serving until 2025 annual meeting.
- She joins the Audit Committee and Science and Technology Committee.
- Annual cash retainers: $40,000 for Board, $8,000 for Audit, $5,000 for Science & Technology.
- Receives initial option for 44,000 shares vesting quarterly over 4 years; annual option for 22,000 shares thereafter.
- Dr. Mackey previously was SVP at Pfizer and serves on other biotech boards (IDEAYA, Avid Bioservices, Cour Pharmaceuticals).

## SEC filing metadata
- accession: 0001104659-22-083431
- form_type: 8-K
- ticker: VYGR
- cik: 0001640266
- company_name: Voyager Therapeutics, Inc.
- filed_at: 2022-07-28T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1640266/000110465922083431/0001104659-22-083431-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1640266/000110465922083431/tm2221989d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-083431
- JSON: https://secwatch.observer/filing/0001104659-22-083431.json
- Plain text: https://secwatch.observer/filing/0001104659-22-083431.txt

## Key facts
- Executive change
  Catherine J. Mackey, Ph.D. was appointed as director at Voyager Therapeutics, Inc..
  - Action: appointed
  - Role: director
  source text: On July 27, 2022, the Board of Directors (the “Board”) of Voyager Therapeutics, Inc. (the “Company”), following the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Catherine J. Mackey, Ph.D. as a director of the Company and as a member of both the Audit Committee and the Science and Technology Committee of the Board, effective August 15, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1640266/000110465922083431/0001104659-22-083431-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.